BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32507974)

  • 1. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation.
    Yaw ACK; Chan EWL; Yap JKY; Mai CW
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2219-2229. PubMed ID: 32507974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
    Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
    Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipopolysaccharide (LPS) stimulation of Pancreatic Ductal Adenocarcinoma (PDAC) and macrophages activates the NLRP3 inflammasome that influences the levels of pro-inflammatory cytokines in a co-culture model.
    Sivam HGP; Chin BY; Gan SY; Ng JH; Gwenhure A; Chan EWL
    Cancer Biol Ther; 2023 Dec; 24(1):2284857. PubMed ID: 38018872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
    Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
    Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.
    Wu D; Chen Y; Sun Y; Gao Q; Li H; Yang Z; Wang Y; Jiang X; Yu B
    Inflammation; 2020 Feb; 43(1):17-23. PubMed ID: 31646445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
    van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCC950 Inhibits NLRP3 Inflammasome and Alleviates Axonal Injures in Early Stages of Diffuse Axonal Injury in Rats.
    Zhao J; Guo X; Wang B; Yang Z; Huang T; Guo D; Zhang M; Song J
    Neurochem Res; 2020 Sep; 45(9):2020-2031. PubMed ID: 32474832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model.
    Sui A; Chen X; Shen J; Demetriades AM; Yao Y; Yao Y; Zhu Y; Shen X; Xie B
    Cell Death Dis; 2020 Oct; 11(10):901. PubMed ID: 33093455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
    Zhang W; Ba G; Tang R; Li M; Lin H
    Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
    Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
    J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice.
    Dempsey C; Rubio Araiz A; Bryson KJ; Finucane O; Larkin C; Mills EL; Robertson AAB; Cooper MA; O'Neill LAJ; Lynch MA
    Brain Behav Immun; 2017 Mar; 61():306-316. PubMed ID: 28003153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome.
    Li H; Guan Y; Liang B; Ding P; Hou X; Wei W; Ma Y
    Eur J Pharmacol; 2022 Aug; 928():175091. PubMed ID: 35714692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
    Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
    Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Huang S; Chen Z; Fan B; Chen Y; Zhou L; Jiang B; Long H; Zhong W; Li X; Li Y
    J Neuroimmunol; 2021 May; 354():577543. PubMed ID: 33714750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation.
    Chen Y; Yang Q; Lv C; Chen Y; Zhao W; Li W; Chen H; Wang H; Sun W; Yuan H
    Cell Prolif; 2021 Feb; 54(2):e12973. PubMed ID: 33382502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
    Sui X; Yang J; Zhang G; Yuan X; Li W; Long J; Luo Y; Li Y; Wang Y
    Toxicology; 2020 Feb; 432():152392. PubMed ID: 32014472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
    Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
    Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
    Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.